The blockade of TIGIT via mAbs reversed the exhaustion of anti-tumor NK cells in multiple tumor models, enhanced the infiltration of activated (CD69+) NK cells into tumors and thereafter improved the OS of the host (233). The gene discussed is CD69; the disease is neoplasm.